Suven Life Sciences Limited (NSE:SUVEN)
India
· Delayed Price · Currency is INR | Market Cap | 41.18B |
| Revenue (ttm) | 75.74M |
| Net Income (ttm) | -1.43B |
| Shares Out | n/a |
| EPS (ttm) | -6.58 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,207,213 |
| Average Volume | 1,575,331 |
| Open | 184.00 |
| Previous Close | 184.97 |
| Day's Range | 181.53 - 190.58 |
| 52-Week Range | 82.95 - 198.54 |
| Beta | 0.64 |
| RSI | 80.67 |
| Earnings Date | May 28, 2025 |
About Suven Life Sciences
Suven Life Sciences Limited, a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders in India, the United States, Europe, and internationally. The company engages in drug discovery and development of new chemical entities in central nervous system diseases. Its product candidates include Masupirdine (SUVN-502) for the treatment of Alzheimer disease and neuropsychiatric symptoms; Samelisant (SUVN-G3031), a histamine 3 recepto... [Read more]
Financial Performance
In 2023, Suven Life Sciences's revenue was 116.93 million, a decrease of -13.99% compared to the previous year's 135.95 million. Losses were -1.05 billion, -11.15% less than in 2022.
Financial StatementsNews
Suven Life Sciences shares surge over 8% after clinical trial update
Shares of Suven Life Sciences Limited surged 8% on January 8, reaching ₹139.00 during the trading session. The sharp rise comes after the company announced the dosing of the first subjects in a Phase-...
Suven Life Sciences initiates Phase-1 clinical trial for SUVN-I6107
Suven Life Sciences Limited has announced the dosing of the first subjects in a Phase-1 clinical trial for SUVN-I6107, a muscarinic M1 positive allosteric modulator (M1 PAM) aimed at treating cognitiv...